Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.

Autor:	Shuford S; KIYATEC, Inc., Greenville, South Carolina, USA., Wilhelm C; KIYATEC, Inc., Greenville, South Carolina, USA., Rayner M; KIYATEC, Inc., Greenville, South Carolina, USA., Elrod A; KIYATEC, Inc., Greenville, South Carolina, USA., Millard M; KIYATEC, Inc., Greenville, South Carolina, USA., Mattingly C; KIYATEC, Inc., Greenville, South Carolina, USA.; USC School of Medicine, Greenville, South Carolina, USA., Lotstein A; KIYATEC, Inc., Greenville, South Carolina, USA.; ECPI University, Greenville, South Carolina, USA., Smith AM; KIYATEC, Inc., Greenville, South Carolina, USA., Guo QJ; KIYATEC, Inc., Greenville, South Carolina, USA.; MUSC College of Medicine, Charleston, South Carolina, USA., O'Donnell L; KIYATEC, Inc., Greenville, South Carolina, USA.; SYNNEX Corporation, Greenville, South Carolina, USA., Elder J; Prisma Health, Greenville, South Carolina, USA., Puls L; Prisma Health, Greenville, South Carolina, USA., Weroha SJ; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Hou X; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Zanfagnin V; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Nick A; Saint Thomas Health/Ascension, Nashville, Tennessee, USA.; Tennessee Oncology, Nashville, Tennessee, USA., Stany MP; Saint Thomas Health/Ascension, Nashville, Tennessee, USA., Maxwell GL; Department of Obstetrics and Gynecology, Inova Fairfax Medical Campus, Falls Church, Virginia, USA., Conrads T; Department of Obstetrics and Gynecology, Inova Fairfax Medical Campus, Falls Church, Virginia, USA., Sood AK; Departments of Gynecologic Oncology and Cancer Biology, MD Anderson Cancer Center, Houston, Texas, USA., Orr D; KIYATEC, Inc., Greenville, South Carolina, USA.; MacuLogix, Inc, Middletown, Pennsylvania, USA., Holmes LM; KIYATEC, Inc., Greenville, South Carolina, USA., Gevaert M; KIYATEC, Inc., Greenville, South Carolina, USA., Crosswell HE; KIYATEC, Inc., Greenville, South Carolina, USA.; Bon Secours St. Francis, Greenville, South Carolina, USA., DesRochers TM; KIYATEC, Inc., Greenville, South Carolina, USA. tessa.desrochers@kiyatec.com.
Jazyk:	angličtina
Zdroj:	Scientific reports [Sci Rep] 2019 Aug 01; Vol. 9 (1), pp. 11153. Date of Electronic Publication: 2019 Aug 01.
DOI:	10.1038/s41598-019-47578-7
Abstrakt:	Although 70-80% of newly diagnosed ovarian cancer patients respond to first-line therapy, almost all relapse and five-year survival remains below 50%. One strategy to increase five-year survival is prolonging time to relapse by improving first-line therapy response. However, no biomarker today can accurately predict individual response to therapy. In this study, we present analytical and prospective clinical validation of a new test that utilizes primary patient tissue in 3D cell culture to make patient-specific response predictions prior to initiation of treatment in the clinic. Test results were generated within seven days of tissue receipt from newly diagnosed ovarian cancer patients obtained at standard surgical debulking or laparoscopic biopsy. Patients were followed for clinical response to chemotherapy. In a study population of 44, the 32 test-predicted Responders had a clinical response rate of 100% across both adjuvant and neoadjuvant treated populations with an overall prediction accuracy of 89% (39 of 44, p < 0.0001). The test also functioned as a prognostic readout with test-predicted Responders having a significantly increased progression-free survival compared to test-predicted Non-Responders, p = 0.01. This correlative accuracy establishes the test's potential to benefit ovarian cancer patients through accurate prediction of patient-specific response before treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.